ISSN 1662-4009 (online)

ey0017.4-14 | New paradigms | ESPEYB17

4.14. Circulating IGF-1 independently predicts blood pressure in children with higher calcium-phosphorus product levels

S Xargay-Torrent , E Dorado-Ceballos , A Benavides-Boixader , E Lizarraga-Mollinedo , B Mas-Pares , M Montesinos-Costa , F De Zegher , L Ibanez , J Bassols , A Lopez-Bermejo

To read the full abstract: J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz101.The aim of this prospective longitudinal study of 521 healthy children (8.8 ± 0.1) was to evaluate the correlation of circulating IGF-I levels with metabolic and cardiovascular parameters and the potential interaction with the Calcium-Phosphorus product (Ca*P). 158 subjects were re-evaluated after a follow-up of 5 years. Baseline IGF-I and IGF-I/IGFBP-3 molar r...

ey0015.3-7 | Congenital hypothyroidism | ESPEYB15

3.7 Mean high-dose L-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism

PE Aleksander , M Bruckner-Spieler , AM Stoehr , E Lankes , P Kuhnen , D Schnabel , A Ernert , W Stablein , ME Craig , O Blankenstein , A Gruters , H Krude

To read the full abstract: J Clin Endocrinol Metab 2018;103:1459-1469The ESPE guidelines on CH recommend an initial LT4 dose of 10-15 microgram/kg per day1. Infants with severe CH, defined by a very low pretreatment TT4 or FT4 concentration, should be treated with the highest initial dose. However, little is known about long-term effects on developmental and...

ey0020.2-7 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

BS Miller , JC Blair , MH Rasmussen , A Maniatis , RJ Kildemoes , J Mori , M Polak , RB Bang , V Bottcher , S Stagi , R Horikawa

Brief summary: This multicenter, randomized, controlled, phase 3 study compared the effects of long-acting GH (Somapacitan; 0.16 mg/kg/wk) with daily GH (Norditropin; 0.034 mg/kg/d), in GHD children. The trial was conducted over 52 weeks, followed by an ongoing 3-year single-group extension period. Similar efficacy and safety for somapacitan compared to daily GH was demonstrated over 52 weeks of treatment.Long-acting growth hormone (LAGH) formulations ha...

ey0020.6-2 | New Mechanisms | ESPEYB20

6.2. Circadian regulation of hippocampal function is disrupted with corticosteroid treatment

MT Birnie , MDB Claydon , O Troy , BP Flynn , M Yoshimura , YM Kershaw , Z Zhao , RCR Demski-Allen , GRI Barker , EC Warburton , ZA Bortolotto , SL Lightman , BL Conway-Campbell

Brief summary: This study investigates the effect of long-acting synthetic glucocorticoids on circadian rhythmicity and hippocampal functionGlucocorticoids exert their effects by binding to glucocorticoid receptors (GRs), which regulate up to ~20% of the genome via both direct (by binding to glucocorticoid responsive elements in promoter regions) and indirect mechanisms (by interacting with bound transcription factors and epigenetic modifiers) (1...

ey0020.9-17 | Patient Care: Bariatric Surgery, New Drugs, and Appropriate Language | ESPEYB20

9.17. Once-weekly semaglutide in adolescents with obesity

D Weghuber , T Barrett , M Barrientos-Perez , I Gies , D Hesse , OK Jeppesen , AS Kelly , LD Mastrandrea , R Sorrig , S Arslanian , STEP TEENS Investigators

Brief summary: This phase 3 double-blind, parallel-group, randomized, placebo-controlled trial over 68 weeks randomised (2:1) 201 adolescents with obesity to receive semaglutide 2.4 mg once weekly or placebo. Both groups also received lifestyle intervention. The primary endpoint was the percentage change in BMI. Treatment with semaglutide produced clinically relevant reductions in BMI and body weight, and improvements in cardiovascular risk factors, which were all significantl...

ey0018.7-1 | Clinical Guidance | ESPEYB18

7.1. Cranial MRI abnormalities and long-term follow-up of the lesions in 770 girls with central precocious puberty

D Helvacıoğlu , S Demircioğlu Turan , T Guran , Z Atay , A Dağcınar , D Bezen , E Karakılıc Ozturan , F Darendeliler , A Yuksel , F Dursun , S Kılınc , S Semiz , S Abalı , M Yıldız , A Onder , A Bereket

J Clin Endocrinol Metab. 2021 Mar 25:dgab190. doi: 10.1210/clinem/dgab190. PMID: 33765130. https://academic.oup.com/jcem/article-abstract/106/7/e2557/6188450?redirectedFrom=fulltextIn brief: This multicentre cohort study explores the frequency, long-term outcomes and potential p...

ey0019.4-3 | Important for clinical practice | ESPEYB19

4.3. Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation

C Jagodzinski , S Mueller , R Kluck , K Froede , L Pavicic , J Gellermann , D Mueller , U Querfeld , D Haffner , M Zivicnjak

Pediatr Nephrol, 2022. 37(4): p. 859-869 PMID: 34542703Brief Summary: This prospective observational cohort study investigated growth rate after kidney transplant in children with chronic kidney disease (CKD) and growth failure, who received or did not receive rhGH treatment before transplantation. Patients pre-treated with rhGH showed better growth rates with taller height SDS at 7 years after transplantation. Positive effects of pre-transplant...

ey0015.7-11 | New genes in hypogonadotropic hypogonadism | ESPEYB15

7.11 KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism

C Xu , A Messina , E Somm , H Miraoui , T Kinnunen , J Acierno , NJ Niederländer , J Bouilly , AA Dwyer , Y Sidis , D Cassatella , GP Sykiotis , R Quinton , C De Geyter , M Dirlewanger , V Schwitzgebel , TR Cole , AA Toogood , JM Kirk , L Plummer , U Albrecht , WF Crowley , M Mohammadi , M Tena-Sempere , V Prevot , N Pitteloud

To read the full abstract: EMBO Mol Med. 2017 Oct;9(10):1379-1397[Comments on 7.10 and 7.11] During embryonic development, GnRH neurons originate in the olfactory placode and migrate through the nasal mesenchyme using the olfactory/vomeronasal axons as a scaffold to reach their final destination in the basal forebrain1,2. Th...

ey0020.2-2 | Important for Clinical Practice | ESPEYB20

2.2. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort

M Maghnie , MB Ranke , ME Geffner , E Vlachopapadopoulou , L Ibanez , M Carlsson , W Cutfield , R Rooman , R Gomez , MP Wajnrajch , A Linglart , R Stawerska , PE Clayton , F Darendeliler , ACS Hokken-Koelega , R Horikawa , T Tanaka , HG Dorr , K Albertsson-Wikland , M Polak , A Grimberg

Brief summary: This study reports data from the full Kabi/Pfizer International Growth Database (KIGS), a large international database including 83803 children treated with rhGH for GHD and non-GHD conditions. The data confirm that rhGH is effective in increasing short-term height gain and adult height in various conditions and validate rhGH safety, with no new serious adverse events reported.KIGS (Kabi/Pfizer International Growth Database), first establi...

ey0019.11-7 | New findings in adipose tissue biology | ESPEYB19

11.7. Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages

MA Guzzardi , L Guiducci , D Campani , F La Rosa , A Cacciato Insilla , A Bartoli , M Cabiati , V De Sena , S Del Ry , S Burchielli , F Bonino , P Iozzo

patricia.iozzo@ifc.cnr.it Int J Obes (Lond) 2022, 46(1):50–58. doi: 10.1038/s41366-021-00941-zBrief Summary: This experimental study was conducted with fa/fa rats that have a homozygous defect in the leptin receptor and therefore severe leptin resistance. The animals develop extreme obesity, diabetes and metabolic syndrome. The study of y...